title: Factors related with the progression of chronic kidney disease.
abstract: BACKGROUND
  Our aims were to determine the rate of progression of chronic kidney disease (CKD) and to identify predictors, with particular emphasis on bone and mineral metabolism.
  
  
  METHODS
  Retrospective and observational study including 300 patients with advanced CKD (61.2% males, 33.1% diabetics; age 65.6±14 years). Mean follow-up time was 19.4±10.1 months. Baseline estimated glomerular filtration rate (eGFR) (MDRD-4) was 22.5±7.18 mL/min. To calculate the rate of decline in eGFR, we used the slope of the regression line between all determinations of eGFR and follow-up time. We calculated the mean values for proteinuria and serum phosphate, calcium, uric acid, and PTH, as well as 24-hour urinary excretion of urea nitrogen over time for each patient. Follow-up was at least 6 months and included at least 4 measurements of eGFR.
  
  
  RESULTS
  The mean rate of decline eGFR (-1.64 mL/min/1.73 m²/year) was inversely correlated with serum phosphate levels (4.3±2.1 mg/dL, P<.001), PTH (256.3±193.7 ng/L, p<.001) and proteinuria (0.84±1.31 g/day, P=.004) and directly correlated with mean serum calcium (P<.001) and the presence of hypertension (P<.02). However, only serum phosphate, serum PTH, and proteinuria persisted as predictors in the multivariate analysis. Stable-GFR patients (positive slope) were older (P=.041) and had lower serum phosphate and PTH levels (P<.01 and P<.01 respectively) and lower proteinuria (P<.01).
  
  
  CONCLUSIONS
  The rate of decrease in eGFR was correlated with serum phosphate and PTH levels and proteinuria. All of these factors can be modified with an adequate treatment.
authors.forename: Claudia
authors.initials: C
authors.lastname: Yuste
authors.forename: Daniel
authors.initials: D
authors.lastname: Barraca
authors.forename: Inés
authors.initials: I
authors.lastname: Aragoncillo-Sauco
authors.forename: Almudena
authors.initials: A
authors.lastname: Vega-Martínez
authors.forename: Soraya
authors.initials: S
authors.lastname: Abad
authors.forename: Úrsula
authors.initials: Ú
authors.lastname: Verdalles-Guzmán
authors.forename: Caridad
authors.initials: C
authors.lastname: Ruiz-Caro
authors.forename: Jara
authors.initials: J
authors.lastname: Ampuero
authors.forename: Juan M
authors.initials: JM
authors.lastname: López-Gómez
mesh_terms: D000368:Aged; D000740:Anemia / Q000188:drug therapy / Q000453:epidemiology; D002118:Calcium / Q000097:blood; D002908:Chronic Disease; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000097:blood / Q000652:urine; D003928:Diabetic Nephropathies / Q000097:blood / Q000503:physiopathology / Q000652:urine; D018450:Disease Progression; D005260:Female; D005919:Glomerular Filtration Rate; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology; D007674:Kidney Diseases / Q000097:blood / Q000503:physiopathology* / Q000652:urine; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011507:Proteinuria / Q000209:etiology; D012189:Retrospective Studies; D012307:Risk Factors; D014527:Uric Acid / Q000097:blood / Q000652:urine
chemical_list: D006397:Hematinics; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010281:Parathyroid Hormone; D014527:Uric Acid; D010758:Phosphorus; D002118:Calcium